Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer

Cancer ◽

10.1002/cncr.29480 ◽

2015 ◽

Vol 121 (18) ◽

pp. 3298-3306 ◽

Author(s):

Karen L. Reckamp ◽

Marianna Koczywas ◽

Mihaela C. Cristea ◽

Jonathan E. Dowell ◽

He-Jing Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

High Dose ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

P1.13-36 Randomized Phase 2 Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2018.08.893 ◽

2018 ◽

Vol 13 (10) ◽

pp. S596

Author(s):

L. Sequist ◽

J. Gray ◽

W. Harb ◽

R. Doebele ◽

M. Modiano ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Wild Type ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Functional Lung Avoidance Radiation Therapy for Stage III Non-Small Cell Lung Cancer: A Double-Blind Randomized Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2015.07.213 ◽

2015 ◽

Vol 93 (3) ◽

pp. S89

Author(s):

B. Yaremko ◽

D.A. Palma ◽

G. Parraga ◽

D. Capaldi ◽

K. Sheikh ◽

...

Keyword(s):

Lung Cancer ◽

Radiation Therapy ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Double Blind ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Final Result of Randomized Phase 2 Trial Comparing Amrubicin (A) with Re-Challenge of Platinum Doublet (P) in Patients (Pts) with Sensitive-Relapsed Small-Cell Lung Cancer (Sclc): Njlcg0702

Annals of Oncology ◽

10.1093/annonc/mdu355.9 ◽

2014 ◽

Vol 25 ◽

pp. iv514 ◽

Author(s):

M. Maemondo ◽

A. Inoue ◽

S. Sugawara ◽

Y. Mori ◽

S. Oizumi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Platinum Doublet

Download Full-text

A randomized phase 2 trial of apatinib vs observation as maintenance treatment following firstline induction chemotherapy in extensive stage small cell lung cancer

Investigational New Drugs ◽

10.1007/s10637-019-00828-x ◽

2019 ◽

Vol 38 (1) ◽

pp. 148-159 ◽

Author(s):

Hao Luo ◽

Liang Zhang ◽

Bo Yang ◽

Yan Feng ◽

Yanli Xiong ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Induction Chemotherapy ◽

Cell Lung Cancer ◽

Maintenance Treatment ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Consolidative Radiotherapy for Limited Metastatic Non–Small Cell Lung Cancer: A Randomized Phase 2 Trial

International Journal of Radiation Oncology*Biology*Physics ◽

10.1016/j.ijrobp.2017.09.010 ◽

2017 ◽

Vol 99 (5) ◽

pp. 1314 ◽

Author(s):

P. Iyengar ◽

V. Tumati ◽

D. Gerber ◽

Z. Wardak ◽

C. Ahn ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Consolidative Radiotherapy ◽

Randomized Phase 2

Download Full-text

Abstract B19: Interim safety results of a randomized phase 2 trial of a tumor vascular disrupting agent fosbretabulin tromethamine (Ca4p) with carboplatin, paclitaxel and bevacizumab in stage IIIB/IV non‐squamous non‐small cell lung cancer

10.1158/1535-7163.targ-09-b19 ◽

2009 ◽

Author(s):

Edward B. Garon ◽

Fairooz Kabbinavar ◽

Jai Balkissoon ◽

Shaio‐Ping Lu ◽

James A. Neidhart ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Vascular Disrupting Agent ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Vascular Disrupting

Download Full-text

Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial

Annals of Oncology ◽

10.1093/annonc/mdw332.04 ◽

2016 ◽

Vol 27 ◽

pp. iv4

Author(s):

D. Kim ◽

M. Tiseo ◽

M. Ahn ◽

K. Reckamp ◽

K. Holmskov Hansen ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Efficacy And Safety ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000183 ◽

2014 ◽

Vol 9 (7) ◽

pp. 1031-1035 ◽

Author(s):

Benjamin Levy ◽

Alexander Spira ◽

Daniel Becker ◽

Tracey Evans ◽

Ian Schnadig ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitor ◽

Phase 2 ◽

Phosphatidylinositol 3 Kinase ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text

Randomized phase 2 trial comparing amrubicin (A) with re-challenge of platinum doublet (P) in patients (pts) with sensitive-relapsed small-cell lung cancer (SCLC).

Journal of Clinical Oncology ◽

10.1200/jco.2014.32.15_suppl.7520 ◽

2014 ◽

Vol 32 (15_suppl) ◽

pp. 7520-7520 ◽

Author(s):

Atsushi Nakamura ◽

Akira Inoue ◽

Makoto Maemondo ◽

Yoshiaki Mori ◽

Satoshi Oizumi ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2 ◽

Platinum Doublet

Download Full-text

Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial

Supportive Care in Cancer ◽

10.1007/s00520-016-3144-z ◽

2016 ◽

Vol 24 (8) ◽

pp. 3495-3505 ◽

Author(s):

Koichi Takayama ◽

Nobuyuki Katakami ◽

Takuma Yokoyama ◽

Shinji Atagi ◽

Kozo Yoshimori ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Japanese Patients ◽

Phase 2 ◽

Small Cell Lung ◽

Phase 2 Trial ◽

Randomized Phase 2

Download Full-text